Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchActive in the last 2 years

Benjamin Haibe‐Kains

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7684-0079; OpenAlex author ID A5010487226. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 8

  1. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer. Co-author DOI 10.1016/j.clcc.2024.05.002↗
  2. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-22-0260↗
  3. Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3389/fgene.2023.1282824↗
  4. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.cell.2021.08.023↗
  5. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  6. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  7. MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature. Last author DOI 10.1038/s41598-019-45165-4↗
  8. Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1200/cci.18.00102↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 4 shared papers, 2019–2023 · strength 0.38
  2. Vandana Sandhu · 4 shared papers, 2019–2020 · strength 0.32
  3. Joanna M. Karasinska · 3 shared papers, 2020–2023 · strength 0.30
  4. Grainne Mary O'Kane · 3 shared papers, 2020–2023 · strength 0.30
  5. David F. Schaeffer · 3 shared papers, 2020–2023 · strength 0.30
  6. Daniel John Renouf · 3 shared papers, 2020–2023 · strength 0.30
  7. George Zogopoulos · 3 shared papers, 2020–2023 · strength 0.30
  8. Ayelet Borgida · 3 shared papers, 2019–2020 · strength 0.22
  9. Jannat Pervin · 1 shared paper, 2023 · strength 0.16
  10. Oliver F. Bathe · 1 shared paper, 2023 · strength 0.16
  11. María Vila-Casadesús · 1 shared paper, 2024 · strength 0.16
  12. Alberto Hernando‐Calvo · 1 shared paper, 2024 · strength 0.16
  13. Aaron Richard Hansen · 1 shared paper, 2024 · strength 0.16
  14. Ana P. Vivancos · 1 shared paper, 2024 · strength 0.16
  15. Lillian Siu · 1 shared paper, 2024 · strength 0.16
  16. Philippe Lucien Bedard · 1 shared paper, 2024 · strength 0.16
  17. Sandra Elisabeth Fischer · 2 shared papers, 2020 · strength 0.14
  18. Sangeetha N. Kalimuthu · 2 shared papers, 2020 · strength 0.14
  19. Runjan Chetty · 2 shared papers, 2020 · strength 0.14
  20. Eugenia Flores Figueroa · 2 shared papers, 2020 · strength 0.14
  21. Ashton Anthony Connor · 2 shared papers, 2020 · strength 0.14
  22. Fieke E. M. Froeling · 2 shared papers, 2020 · strength 0.14
  23. Robert C. Grant · 2 shared papers, 2020 · strength 0.14
  24. Michelle Chan‐Seng‐Yue · 2 shared papers, 2020 · strength 0.14
  25. James Thomas Topham · 2 shared papers, 2020 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.